ovarian cancer
your most complete directory for cancer information and medications Enter here
cancer, breast cancer, blood cancer, bile duct cancer, adrenal cancer, bone marrow cancer, bone cancer, bone cancer symptoms, breast cancer detection, breast cancer prevention, breast cancer research, breast cancer signs and symptoms, breast cancer statistics, breast cancer survival rates, breast cancer treatment, cancer drugs, cancer care, bladder cancer, bowel cancer, brest cancer, cancer clinic, cancer clinical trials, cancer research, cancer of the liver, cancer of the pancreas, cancer de colon, cancer information, cancer prostate treatment, cancer cells, cancer horoscope, alternative cancer treatmentAll of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6
All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6
Enter here - your most complete directory for cancer information and medications
ovarian cancer
| ovarian cancer symptoms | ovarian cancer treatment | prostate cancer early detection | prostate cancer symptoms |
| prostate cancer treatment | prostate cancer |
| best cancer therapy - Enter here to find information about the best cancer therapies available. We can set you up with a specialist who can help you find the best cancer therapy to suit your cancer and needs. |
| cancer therapy options - Our company has been serving the world medical community for more than 100 years, producing high-quality products that respond to the needs of health care providers worldwide. As one of the world's leading designers and manufacturers of cancer treatment systems, it is our mission to make a significant contribution to the treatment and cure of cancer for patients and their families. |
2003 cancer-site.com.
All Rights Reserved. The products mentioned are trademarks of their respective owners and are not owned by us. Read our privacy guidelines.